Medullary thyroid carcinoma: Role of genetic testing and calcitonin measurement

Annals of Clinical Biochemistry

Volumn 38, Issue 3, 2001, Pages 168-179

  Lips, Cornelis J M ^a   Höppener, Jo W M ^a   Thijssen, Jos H H ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN;

CALCITONIN BLOOD LEVEL; CHEMOLUMINESCENCE; DISEASE COURSE; DNA DETERMINATION; FAMILIAL INCIDENCE; FOLLOW UP; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HUMAN; MOLECULAR BIOLOGY; PHENOTYPE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTO ONCOGENE; RELATIVE; REVIEW; THYROID MEDULLARY CARCINOMA; THYROID NODULE;

CALCITONIN; CARCINOMA; DROSOPHILA PROTEINS; EXONS; FEMALE; GENETIC SCREENING; GENOTYPE; HUMANS; INTRONS; MALE; MODELS, GENETIC; PHENOTYPE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES; SENSITIVITY AND SPECIFICITY; SEX FACTORS; THYROID NEOPLASMS;

EID: 0035022302     PISSN: 00045632     EISSN: None     Source Type: Journal    
DOI: 10.1258/0004563011900614     Document Type: Review

References (79)

1. 1 Horn RC Jr. Carcinoma of the thyroid: description of a distinctive morphological variant and report of seven cases. Cancer 1951; 4: 697-707
2. 2 Hazard JB, Hawk WK, Crile G Jr. Medullary (solid) carcinoma of the thyroid - a clinicopathological entity. J Clin Endocrinol Metab 1959; 19: 152-61
3. 3 Sipple JH. The association of pheochromocytoma with carcinoma of the thyroid gland. Am J Med 1961; 31: 163-6
4. 4 Cushman P Jr. Familial endocrine tumours: report of two unrelated kindreds affected with pheochromocytoma, one also with multiple thyroid carcinomas. Am J Med 1962; 32: 352-60
5. 5 Farndon JR, Leight GS, Dilley WG, Baylin SB, Smallridge RC, Harrison TS, et al. Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. Br J Surg 1986; 73: 278-81
6. 6 Raue F. German MTC/MEN registry. German MTC/MEN Study Group. Langenbeck's Arch Surg 1998; 383: 334-6
7. 7 Mathew CG, Chin KS, Easton DF, Thorpe K, Carter C, Liou GI, et al. A linked genetic marker for multiple endocrine neoplasia syndrome type 2A on chromosome 10. Nature 1987; 328: 527-8
8. 8 Mulligan LM, Kwok JB, Healy CS, Elsdon MJ, Eng C, Gardner E, et al. Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia syndrome type 2A. Nature 1993; 363: 458-60
9. 9 Donis-Keller H, Dou S, Chi D, Carlson KH, Toshima K, Lairmore TC, et al. Mutations in the RET proto-oncogene are associated with MEN2A and FMTC. Hum Mol Genet 1993; 2: 851-6
10. 10 Hofstra RMW, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia syndrome type 2B and sporadic medullary thyroid carcinoma. Nature 1994; 367: 375-6
11. 11 Eng C, Mulligan LM. Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and Hirschsprung disease. Hum Mutat 1997; 9: 97-109
12. 12 Höppener JWM, Steenbergh PH, Zandberg J, Geurts van Kessel AHM, Lips CJM, Jansz HS. A third human CALC (pseudo) gene on chromosome II. FEBS Lett 1988; 233: 57-63
13. 13 Mosselman S, Höppener JWM, Zandberg J, Van Mansfeld AJM, Geurts van Kessel AHM, Lips CJM, et al. Islet amyloid polypeptide: identification and chromosomal localization of the human gene. FEBS Lett 1988; 239: 227-32
14. 14 Wimalawansa SJ. Amylin, calcitonin gene-related peptide, calcitonin, and adrenomedullin: a peptide superfamily. Crit Rev Neurobiol 1997; 11: 167-239
15. 15 Bühlmann N, Leuthäuser K, Muff R, Fischer JA, Born W. A receptor activity modifying protein (RAMP) 2-dependent adrenomedullin receptor is calcitonin gene-related peptide receptor when coexpressed with human RAMP1. Endocrinology 1999; 140: 2883-90
16. 16 Muff R, Bühlmann N, Fischer JA, Born W. An amylin receptor is revealed following co-transfection of a calcitonin receptor with activity modifying proteins-1 or -3. Endocrinology 1999; 140: 2924-7
17. 17 Hansford JR, Mulligan LM. Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. J Med Genet 2000; 37: 817-27
18. 18 Carlson KM, Bracamontes J, Jackson CE, Clark R, Lacroix A, Wells SA Jr, et al. Parent-of-origin effects in multiple endocrine neoplasia type 2B. Am J Hum Genet 1994; 55: 1076-82
19. 19 Komminoth P, Roth J, Muletta-Feurer S, Saremaslani P, Seelentag WKF, Heitz PU. RET proto-oncogene point mutations in sporadic neuroendocrine tumors. J Clin Endocrinol Metab 1996; 81: 2041-6
20. 20 Wolfe HJ, Delellis RA. Familial medullary thyroid carcinoma and C-cell hyperplasia. Clin Endocrinol Metab 1981; 10: 351-65
21. 21 Lips CJM, Landsvater RM, Höppener JWM, Geerdink RA, Blijham GH, Jansen-Schillhorn van Veen J, et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia syndrome type 2A. N Engl J Med 1994; 331: 828-35
22. 22 Utiger RD. Medullary thyroid carcinoma, genes, and the prevention of cancer. N Engl J Med 1994; 331: 870-1
23. 23 Moers AMJ, Landsvater RM, Schaap C, Jansen-Schillhorn van Veen JM, de Valk IAJ, Blijham GH, et al. Familial medullary thyroid carcinoma: not a distinct entity? Genotype-phenotype correlation in a large family: familial medullary thyroid carcinoma revisited. Am J Med 1996; 101: 635-41
24. 24 Zedenius J, Larsson C, Bergholm U, Bovee J, Svensson A, Hallergren B, et al. Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 1995; 80: 3088-90
25. 25 Vasen HFA, van der Feltz, Raue F, Nieuwenhuyzen Kruseman A, Koppeschaar HPF, Pieters G, et al. The natural course of multiple endocrine neoplasia syndrome type 2B: a study of 18 cases. Arch Int Med 1992; 152: 1250-2
26. 26 Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. J Am Med Assoc 1996; 276: 1575-9
27. 27 Pacini F, Fontanelli M, Fugazzola L, Elisei R, Romei C, Di Coscio G, et al. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 1994; 78: 826-9
28. 28 Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med 1993; 328: 553-9
29. 29 Tan GH, Gharib H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med 1997; 268: 226-31
30. 30 Vierhapper H, Raber W, Bieglmayer C, Kaserer K, Weinhäusl A, Niederle B. Routine measurement of plasma CT in nodular thyroid diseases. J Clin Endocrinol Metab 1997; 82: 1589-93
31. 31 Mayr B, Brabant G, von zur Muhlen A. Incidental detection of familial medullary thyroid carcinoma by calcitonin screening for nodular thyroid disease. Eur J Endocrinol 1999; 141: 286-9
32. 32 Dunn JT. When is a thyroid nodule a sporadic medullary carcinoma? J Clin Endocrinol Metab 1994; 78: 824-5
33. 33 Henry JF, Denizot A, Puccini M, Gramatica L, Kvachenyuk A, Conte Devolx B, et al. Latent subclinical medullary thyroid carcinoma: diagnosis and treatment. World J Surg 1998; 22: 752-7
34. 34 Heshmati HM, Gharib H, Van Heerden JA, Sizemore GW. Advances and controversies in the diagnosis and management of medullary thyroid carcinoma. Am J Med 1997; 103: 60-9
35. 35 Niccoli P, Wion-Barbot N, Caron P, Henry JF, De Micco C, Saint André JP, et al. Interest in routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. The French MTC Study Group. J Clin Endocrinol Metab 1997; 82: 338-41
36. 36 Horvit PK, Gagel RF. The goitrous patient with an elevated serum calcitonin - what to do? J Clin Endocrinol Metab 1997; 82: 335-7
37. 37 Hackeng WHL, Schellekens APM, Schopman W. A radioimmunoassay for human calcitonin. Horm Metab Res 1970; 2: 311
38. 38 Body JJ, Heath H. Estimates of circulating monomeric calcitonin: physiological studies in normal and thyroidectomized man. J Clin Endocrinol Metab 1983; 57: 897-903
39. 39 Motte P, Vauzelle P, Gardet P, Ghillani P, Caillon B, Parmentier C, et al. Construction and clinical validation of a sensitive and specific assay for serum mature calcitonin using monoclonal antipeptide antibodies. Clin Chim Acta 1988; 174: 35-54
40. 40 Perdrisot R, Birgorgne JC, Guilloteau D, Jallet P. Monoclonal immunoradiometric assay of calcitonin improves investigation of familial medullary thyroid carcinoma. Clin Chem 1990; 36: 381-3
41. 41 Tobler PH, Tschopp FA, Dambacher MA, Born W, Fischer JA. Identification and characterization of calcitonin forms in plasma and urine of normal subjects and medullary thyroid carcinoma patients. J Clin Endocrinol Metab 1983; 57: 749-54
42. 42 Grauer A, Raue F, Ziegler R. Clinical usefulness of a new chemiluminescent two-site immunoassay for human calcitonin. Exp Clin Endocrinol Diabetes 1998; 106: 289-91, 353-9
43. 43 Engelbach M, Görges R, Forst T, Pfützner A, Dawood R, Heerdt S, et al. Improved diagnostic methods in the follow-up of medullary thyroid carcinoma by highly specific calcitonin measurements. J Clin Endocrinol Metab 2000; 85: 1890-4
44. 44 Deftos LJ, Weisman MH, Williams GW, Karpf DB, Frumar AM, Davidson BJ. et al. Influence of age and sex on plasma calcitonin in human beings. N Engl J Med 1980; 302: 1351-3
45. 45 Shamonki IM, Frumar AM, Tataryn IV, Meldrum DR, Davidson BH, Parthemore JG, et al. Age-related changes of calcitonin secretion in females. J Clin Endocrinol Metab 1980; 50: 437-9
46. 46 Gibson WGH, Croker BP, Cox C. C-cell populations in normal children and young adults. Lab Invest 1980; 42: 119-20
47. 47 Gibson WGH, Peng T-C, Croker BP. Age associated C-cell hyperplasia in the human thyroid. Am J Pathol 1982; 106: 388-93
48. 48 O'Toole K, Fenoglio-Preiser C, Pushparaj N. Endocrine changes associated with the human aging process: III. Effect of age on the number of calcitonin immunoreactive cells in the thyroid gland. Hum Pathol 1985; 16: 991-1000
49. 49 Engelbach M, Heerdt S, Görges R, Kunt T, Pfützner A, Forst T, et al. Is there an ectopic secretion of monomeric calcitonin in human beings? Langenbeck's Arch Surg 1998; 383: 456-9
50. 50 Tashjian AH Jr, Howland BG, Melvin KEW, Hill CS Jr. Immunoassay of human calcitonin. (Clinical measurement, relation to serum calcium, and studies in patients with medullary thyroid carcinoma). N Engl J Med 1970; 283: 890-5
51. 51 Deftos LJ. Radioimmunoassay for calcitonin in medullary thyroid carcinoma. JAMA 1974; 227: 403-6
52. 52 Garrett JE, Tamir H, Kifor O, Simin RT, Rogers KV, Mithal A, et al. Calcitonin-secreting cells of the thyroid express an extracellular calcium receptor gene. Endocrinology 1995; 136: 5202-11
53. 53 Care AD. The regulation of the secretion of calcitonin. Bone Miner 1992; 16: 182-5
54. 54 Hennessey JF, Wells SA Jr, Ontjes DA, Cooper CW. A comparison of pentagastrin injection and calcium infusion as provocative agents for the detection of medullary thyroid carcinoma. J Clin Endocrinol Metab 1974; 39: 487-95
55. 55 Parthemore JG, Bronzert D, Deftos LJ, Roberts G. A short calcium infusion test in the diagnosis of medullary thyroid carcinoma. J Clin Endocrinol Metab 1974; 39: 108-11
56. 56 Telenius-Berg M, Almqvist S, Berg B, Hedner P, Ingemansson S, Tibblin S, et al. Screening for medullary carcinoma of the thyroid in families with Sipple's syndrome: evaluation of new stimulation tests. Eur J Clin Invest 1977; 7: 7-16
57. 57 Lips CJM, Minder WH, Leo JR, Alleman A, Hackeng WHL. Evidence of multicentric origin of the multiple endocrine neoplasia syndrome type 2A (Sipple's syndrome) in a large family in the Netherlands. Am J Med 1978; 64: 569-78
58. 58 Deftos LJ. Calcitonin secretion and medullary thyroid carcinoma. Am Assoc Clin Chem 1990; 8: 7-24
59. 59 Whang KT, Steinwald PM, White JC, Nylen ES, Snider RH, Simon GL, et al. Related serum calcitonin precursors in sepsis and systemic inflammation. J Clin Endocrinol Metab 1998; 83: 3296-301
60. 60 Hillyard CJ, Coombes RC, Greenberg PB, Galante LS, McIntyre I. Calcitonin in breast and lung cancer. Clin Endocrinol (Oxf) 1976; 5: 1-8
61. 61 Milhaud G, Calmette C, Taboulet J, Julienne A, Moukthar MS. Hypersecretion of calcitonin in neoplastic conditions. Lancet 1974; i: 462-3
62. 62 Silva OL, Becker KL, Primack A, Doppman J, Snider RH. Ectopic secretion of calcitonin by oat cell carcinoma. N Engl J Med 1974; 290: 1122-4
63. 63 Di Sant'Agnese PA. Neuroendocrine differentiation in human prostatic carcinoma. Hum Pathol 1992; 23: 287-96
64. 64 Marsh DJ, Andrew SD, Eng C, Learoyd DL, Capes AG, Pojer R, et al. Germline and somatic mutations in an oncogene: RET mutations in inherited medullary thyroid carcinoma. Cancer Res 1996; 218: 606-9
65. 65 Van Heurn LW, Schaap C, Sie G, Haagen AA, Gerver WJ, Freling G, et al. Predictive DNA testing for multiple endocrine neoplasia 2: a therapeutic challenge of prophylactic thyroidectomy in very young children. J Pediatr Surg 1999; 34: 568-71
66. 66 Fleming JB, Lee JF, Bouvet M, Schultz PN, Sherman SI, Sellin RV, et al. Surgical strategy for the treatment of medullary thyroid carcinoma. Ann Surg 1999; 230: 697-707
67. 67 Evans DB, Fleming JB, Lee JE, Cote G, Gagel RF. The surgical treatment of medullary thyroid carcinoma. Semin Surg Oncol 1999; 16: 50-63
68. 68 Cohen R, Campos J-M, Salaün C, Heshmati HM, Kraimps J-L, Proye C, et al. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in MTC. J Clin Endocrinol Metab 2000; 85: 919-22
69. 69 Fugazzola L, Pinchera A, Luchetti F, Iacconi P, Miccoli P, Romei C. et al. Disappearance rate of serum calcitonin after total thyroidectomy for medullary thyroid carcinoma. Int J Biol Markers 1994; 9: 21-4
70. 70 Girelli ME, Dotto S, Nacamulli D, Piccolo M, De Vido D, Russo T, et al. Prognostic value of early postoperative calcitonin level in medullary thyroid carcinoma. Tumori 1994; 80: 113-7
71. 71 Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma; results in 899 patients. Clin Endocrinol (Oxf) 1998; 48: 265-73
72. 72 Niccoli-Sire P, Murat A, Baudin E, Henry JF, Proye C, Bigorgne JC, et al. Early or prophylactic thyroidectomy in MEN2/FMTC gene carriers: results in 71 thyroidectomized patients. The French Calcitonin Tumours Study Group (GETC). Eur J Endocrinol 1999; 141: 468-74
73. 73 Moley JF, Dilley WG, DeBenedetti MK. Improved results of cervical reoperation for medullary thyroid carcinoma. Ann Surg 1997; 225: 734-43
74. 74 Gimm O, Dralle H. Reoperation in metastasizing medullary thyroid carcinoma: is a tumor stage-oriented approach justified? Surgery 1997; 122: 1124-31
75. 75 Moley JF, DeBenedetti MK. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg 1999; 229: 880-8
76. 76 Bergholm U, Bergstrom R, Ekbom A. Long-term follow-up of patients with medullary carcinoma of the thyroid. Cancer 1997; 79: 132-8
77. 77 Zhuang Z, Bertheau P, Emmert-Buck MR, Liotta LA, Gnarra J, Linehan WM, et al. A microdissection technique for archival DNA analysis of specific cell populations in lesions <1 mm in size. Am J Pathol 1995; 146: 620-5
78. 78 Lee JY, Dong SM, Kim SY, Yoo NJ, Lee SH, Park WS. A simple, precise and economical microdissection technique for analysis of genomic DNA from archival tissue sections. Virchows Arch 1998; 433: 305-9
79. 79 Löffler J, Trojowsky A, Casati B, Kroisel M, Uterman G. Homozygosity for the W151X stop mutation in the Δ7-sterol reductase gene (DHCR7) causing a lethal form of Smith-Lemli-Opitz syndrome: Retrospective molecular diagnosis. Am J Med Genet 2000; 95: 174-7